$559 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 128 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CELG | CELGENE CORP | $32,468,000 | +4.4% | 250,000 | 0.0% | 5.52% | -9.3% | |
| PFE | PFIZER INC | $13,100,000 | -1.8% | 390,000 | 0.0% | 2.23% | -14.6% | |
| ARRY | ARRAY BIOPHARMA INC | $5,859,000 | -6.4% | 700,000 | 0.0% | 1.00% | -18.6% | |
| FGEN | FIBROGEN INC | $5,352,000 | +31.0% | 165,700 | 0.0% | 0.91% | +13.8% | |
| V | VISA INC | $4,966,000 | +5.5% | 52,951 | 0.0% | 0.84% | -8.3% | |
| SELB | SELECTA BIOSCIENCES INC | $4,539,000 | +38.7% | 228,534 | 0.0% | 0.77% | +20.5% | |
| RTRX | RETROPHIN INC | $4,055,000 | +5.0% | 209,131 | 0.0% | 0.69% | -8.7% | |
| GOOGL | ALPHABET INCcap stk cl a | $4,040,000 | +9.6% | 4,346 | 0.0% | 0.69% | -4.7% | |
| ADMS | ADAMAS PHARMACEUTICALS INC | $3,419,000 | -0.1% | 195,500 | 0.0% | 0.58% | -13.2% | |
| DBVT | DBV TECHNOLOGIES S Asponsored adr | $3,220,000 | +1.4% | 90,167 | 0.0% | 0.55% | -11.9% | |
| TXMD | THERAPEUTICSMD INC | $3,057,000 | -26.8% | 580,000 | 0.0% | 0.52% | -36.4% | |
| EIGR | EIGER BIOPHARMACEUTICALS INC | $3,044,000 | -31.0% | 385,301 | 0.0% | 0.52% | -40.1% | |
| STML | STEMLINE THERAPEUTICS INC | $2,760,000 | +7.6% | 300,000 | 0.0% | 0.47% | -6.4% | |
| CLSD | CLEARSIDE BIOMEDICAL INC | $2,733,000 | +14.7% | 300,000 | 0.0% | 0.46% | -0.4% | |
| SNA | SNAP ON INC | $2,496,000 | -6.3% | 15,797 | 0.0% | 0.42% | -18.6% | |
| SGEN | SEATTLE GENETICS INC | $1,863,000 | -17.7% | 36,000 | 0.0% | 0.32% | -28.3% | |
| MRNS | MARINUS PHARMACEUTICALS INC | $1,824,000 | -22.6% | 1,331,421 | 0.0% | 0.31% | -32.8% | |
| ARDX | ARDELYX INC | $1,760,000 | -59.7% | 345,000 | 0.0% | 0.30% | -64.9% | |
| PRQR | PROQR THRAPEUTICS N V | $1,716,000 | +4.0% | 330,000 | 0.0% | 0.29% | -9.6% | |
| SPNS | SAPIENS INTL CORP N V | $1,648,000 | -13.1% | 147,306 | 0.0% | 0.28% | -24.5% | |
| TSEM | TOWER SEMICONDUCTOR LTD | $1,602,000 | +3.5% | 67,155 | 0.0% | 0.27% | -10.2% | |
| EDGE | EDGE THERAPEUTICS INC | $1,539,000 | +12.6% | 150,000 | 0.0% | 0.26% | -2.2% | |
| VTVT | VTV THERAPEUTICS INCcl a | $1,491,000 | -24.1% | 300,000 | 0.0% | 0.25% | -34.1% | |
| MGNX | MACROGENICS INC | $1,422,000 | -5.8% | 81,200 | 0.0% | 0.24% | -18.0% | |
| ISHARES TRcall | $1,415,000 | +1.7% | 100 | 0.0% | 0.24% | -11.8% | ||
| MA | MASTERCARD INCORPORATEDcl a | $1,400,000 | +8.0% | 11,525 | 0.0% | 0.24% | -5.9% | |
| EVOK | EVOKE PHARMA INC | $1,280,000 | -17.4% | 500,000 | 0.0% | 0.22% | -28.4% | |
| VTGN | VISTAGEN THERAPEUTICS INC | $1,017,000 | -4.6% | 544,100 | 0.0% | 0.17% | -16.8% | |
| ITEK | INOTEK PHARMACEUTICALS CORP | $763,000 | -5.1% | 401,764 | 0.0% | 0.13% | -17.2% | |
| UNH | UNITEDHEALTH GROUP INC | $371,000 | +13.1% | 2,000 | 0.0% | 0.06% | -1.6% | |
| MHK | MOHAWK INDS INC | $266,000 | +5.6% | 1,100 | 0.0% | 0.04% | -8.2% | |
| SEE | SEALED AIR CORP NEW | $201,000 | +2.6% | 4,500 | 0.0% | 0.03% | -10.5% | |
| LOW | LOWES COS INC | $202,000 | -5.6% | 2,600 | 0.0% | 0.03% | -19.0% | |
| SERV | SERVICEMASTER GLOBAL HLDGS I | $196,000 | -6.2% | 5,000 | 0.0% | 0.03% | -19.5% | |
| ULTI | ULTIMATE SOFTWARE GROUP INC | $168,000 | +7.7% | 800 | 0.0% | 0.03% | -3.3% | |
| CMG | CHIPOTLE MEXICAN GRILL INC | $166,000 | -6.7% | 400 | 0.0% | 0.03% | -20.0% | |
| TRIP | TRIPADVISOR INC | $153,000 | -11.6% | 4,000 | 0.0% | 0.03% | -23.5% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.